Journal of Transplantation
Volume 2017 (2017), Article ID 5646858, 5 pages
https://doi.org/10.1155/2017/5646858
Research Article
Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored
1Department of Nephrology, Hospital del Salvador, Santiago de Chile, Chile
2Faculty of Medicine, Universidad de Chile, Santiago de Chile, Chile
3Faculty of Medicine, Clínica Alemana, Universidad del Desarrollo, Santiago de Chile, Chile
Correspondence should be addressed to Fernando González; lc.cu@flaznogf
Received 3 July 2016; Revised 13 November 2016; Accepted 25 December 2016; Published 26 January 2017
Academic Editor: Raman V. Venkataramanan
Copyright © 2017 Fernando González et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- R. Shapiro, J. B. Young, E. L. Milford, J. F. Trotter, R. T. Bustami, and A. B. Leichtman, “Immunosuppression: evolution in practice and trends, 1993–2003,” American Journal of Transplantation, vol. 5, no. 4, pp. 874–886, 2005. View at Publisher · View at Google Scholar · View at Scopus
- R. Shapiro, “Low toxicity immunosuppressive protocols in renal transplantation,” Keio Journal of Medicine, vol. 53, no. 1, pp. 18–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
- R. Venkataramanan, L. M. Shaw, L. Sarkozi et al., “Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients,” Journal of Clinical Pharmacology, vol. 41, no. 5, pp. 542–551, 2001. View at Publisher · View at Google Scholar · View at Scopus
- R. P. Kershner and W. E. Fitzsimmons, “Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation,” Transplantation, vol. 62, no. 7, pp. 920–926, 1996. View at Publisher · View at Google Scholar · View at Scopus
- W. J. Jusko, A. W. Thomson, J. Fung et al., “Consensus document: therapeutic monitoring of tacrolimus (FK-506),” Therapeutic Drug Monitoring, vol. 17, no. 6, pp. 606–614, 1995. View at Google Scholar
- Approval letter, ANDA 65-461, November 2010, http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/065461s000ltr.pdf.
- B. M. Davit, P. E. Nwakama, G. J. Buehler et al., “Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration,” Annals of Pharmacotherapy, vol. 43, no. 10, pp. 1583–1597, 2009. View at Publisher · View at Google Scholar · View at Scopus
- S. H. Haidar, B. Davit, M.-L. Chen et al., “Bioequivalence approaches for highly variable drugs and drug products,” Pharmaceutical Research, vol. 25, no. 1, pp. 237–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
- Tacrolimus (Prograf™) Prescribing Information, Astellas Pharma US, Inc., Deerfield, Ill, USA, 2011, http://www.astellas.us/docs/prograf.pdf.
- D. Anglicheau, M. Flamant, M. H. Schlageter et al., “Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation,” Nephrology Dialysis Transplantation, vol. 18, no. 11, pp. 2409–2414, 2003. View at Publisher · View at Google Scholar · View at Scopus
- G. B. Klintmalm, “Immunosuppression, generic drugs and the FDA,” American Journal of Transplantation, vol. 11, no. 9, pp. 1765–1766, 2011. View at Publisher · View at Google Scholar · View at Scopus
- C. R. Ensor, J. Trofe-Clark, S. Gabardi, L. M. McDevitt-Potter, and M. A. Shullo, “Generic maintenance immunosuppression in solid organ transplant recipients,” Pharmacotherapy, vol. 31, no. 11, pp. 1111–1119, 2011. View at Publisher · View at Google Scholar · View at Scopus
- R. R. Alloway, B. Sadaka, J. Trofe-Clark, A. Wiland, and R. D. Bloom, “A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients,” American Journal of Transplantation, vol. 12, no. 10, pp. 2825–2831, 2012. View at Publisher · View at Google Scholar · View at Scopus
- D. M. Kirking, F. J. Ascione, C. A. Gaither, and L. S. Welage, “Economics and structure of the generic pharmaceutical industry,” Journal of the American Pharmaceutical Association (1996), vol. 41, no. 4, pp. 578–584, 2001. View at Publisher · View at Google Scholar · View at Scopus
- J. D. Momper, T. A. Ridenour, K. S. Schonder, R. Shapiro, A. Humar, and R. Venkataramanan, “The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function,” American Journal of Transplantation, vol. 11, no. 9, pp. 1861–1867, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. Reinhard, E. J. Erlandsen, and E. Randers, “Biological variation of cystatin C and creatinine,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 69, no. 8, pp. 831–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
- F. González and R. Valjalo, “Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful,” World Journal of Transplantation, vol. 5, no. 4, pp. 338–347, 2015. View at Publisher · View at Google Scholar
- L. M. McDevitt-Potter, B. Sadaka, E. M. Tichy, C. C. Rogers, and S. Gabardi, “A multicenter experience with generic tacrolimus conversion,” Transplantation, vol. 92, no. 6, pp. 653–657, 2011. View at Publisher · View at Google Scholar · View at Scopus
- H. Müller, S. Solari, C. Zuñiga et al., “Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile,” Transplantation Proceedings, vol. 40, no. 3, pp. 705–707, 2008. View at Publisher · View at Google Scholar · View at Scopus